ASCO 2015 Highlights

Ribociclib-Letrozole Combination Potentially Practice-Changing in Advanced Breast Cancer
By Phoebe Starr
ESMO 2016, ESMO
November 2016, Vol 7, No 10
Copenhagen, Denmark—The addition of the selective cyclin-dependent kinase (CDK) 4/6 inhibitor ribociclib to letrozole (Femara) significantly improved progression-free survival (PFS) in patients with hormone receptor (HR)-positive advanced breast cancer. Compared with letrozole alone, the combination of ribociclib plus letrozole improved PFS by 44%.
Read Article
The Growing Shift Toward Value-Based Drug Pricing
By Jessica Miller
Value in Oncology
November 2016, Vol 7, No 10
Boston, MA—Drug pricing in the pharmaceutical industry came under scrutiny at the recent War on Cancer forum organized by The Economist. An expert panel discussed the disassociation between the actual benefits of cancer drugs and their prices.
Read Article
Who Should Attend Meetings
Who Should Attend Meetings
By Michael Kolodziej, MD
Videos
Michael Kolodziej, MD,  talks about who would benefit in attending such conferences, and some of the takeaways from such meetings.
Read Article
Emerging Trends
Emerging Trends
By Gary Palmer, MD
Videos
Gary Palmer, MD, JD, MBA, MPH talks about the challenges related to costs facing community oncologists and some of the consequences of it.
Read Article
Cost and Quality
Cost and Quality
By Michael Kolodziej, MD
Videos
Michael Kolodziej, MD, talks about how oncologists' perspectives have changed to understand that cost and quality do not have to be at odds with one another.
Read Article
Surveying the Cancer Care Landscape
Surveying the Cancer Care Landscape
By Gary Palmer, MD
Videos
Gary Palmer, MD, JD, MBA, MPH points out the value for oncologists, industry, and the payers to know where oncology is going in order to stay current of the trends and its future.
Read Article
Biology, Genetics Guide Diagnosis and Treatment of Thyroid Cancers
By Charles Bankhead
Personalized Medicine, Thyroid Cancer
October 2016, Vol 7, No 9
Recent advances in the management of thyroid cancer have evolved directly from improved knowledge of the underlying genetics and molecular biology, an understanding that will continue to improve in the future, according to a recent review.
Read Article

Page 147 of 330

Stay In The Know

Stay up to date on the matters of value in cancer by signing up for the free, bi-monthly VBCC print publication and VBCC weekly e‑newsletter.

Subscribe
Amplity
© Amplity, Inc. All Rights Reserved. Privacy Policy.